Confronto tra ixekizumab e adalimumab nel trattamento della psoriasi ungueale nei pazienti con artrite psoriasica e con psoriasi cutanea moderata-severa: risultati a 24 settimane di uno studio multicentrico, randomizzato, in aperto, in singolo cieco (SPIRIT-H2H)
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Messaggi chiave
- La psoriasi ungueale è comune nei pazienti con artrite psoriasica e psoriasi cutanea, colpendo fino all’80%-90% dei pazienti nel corso della vita.
- Questa analisi post-hoc dello studio SPIRIT-H2H (NCT03151551) confronta l’efficacia dell’inibitore dell’IL-17A ixekizumab e dell’inibitore del TNF-alfa adalimumab nel trattamento della psoriasi ungueale alla 24a settimana nei pazienti con artrite psoriasica attiva e psoriasi moderata-severa.
- In questa analisi post-hoc, ixekizumab (80,0%) ha mostrato tassi di risoluzione complete della malattia ungueale significativamente maggiori rispetto ad adalimumab (52,5%) alla 24a settimana, confermando la già stabilita efficacia di ixekizumab nella psoriasi ungueale.
- Ciò conferma la già stabilita efficacia di ixekizumab nella psoriasi ungueale.
Presenting Author
Saxon D. Smith, MBChB, MHL, PhD
Northern Clinical School, Sydney Medical School, The University of Sydney
Sydney, Australia
Dr Saxon D Smith is a Fellow of the Australasian College of Dermatologists. He graduated medicine from the University of Otago, Dunedin, New Zealand, and has a Master Degree in Health Law from the University of Sydney. He completed his Doctor of Philosophy (Medicine) at the University of Sydney.
Dr Smith is the principal dermatologist at The Dermatology and Skin Cancer Centre in Gosford and St Leonards, NSW, Australia. He has been a clinical supervisor for dermatology trainees, higher degree by research students, and University of Sydney Doctorate of Medicine (MD) research supervisor/tutor. He has performed research in a broad range of areas in medical and surgical dermatology including adult and paediatric atopic dermatitis, adult and paediatric psoriasis, hidradentitis suppurativa, as well as the surgical and non-surgical management of non-melanoma skin cancer and melanoma. He is also currently involved in multiple pharmaceutical trials from phase II to phase IV.
Dr Smith has been a key note speaker and invited speaker to national and international conferences. He has over 75 peer reviewed journal publications and over 100 published abstracts.
Author disclosures
Saxon D. Smith: Advisory Panel: Abbvie, Biogen, Eli Lilly and Company, Janssen-Cilag, Johnson and Johnson Consumer Products Company, Novartis, Pfizer, Sanofi Genzyme; Research Support: Abbvie, BMS, Eli Lilly and Company, Novartis, Sanofi Genzyme, UCB, Regeneron; Speaker’s Bureau: Abbvie, Eli Lilly and Company, Leo, Novartis; Honoraria: Energizer Holdings, Inc.
